Stay updated on KTE-C19 + Atezolizumab in DLBCL Clinical Trial
Sign up to get notified when there's something new on the KTE-C19 + Atezolizumab in DLBCL Clinical Trial page.

Latest updates to the KTE-C19 + Atezolizumab in DLBCL Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedA site-wide NIH notice announces updates to terminology, including the use of “Super Intelligence” in place of “Artificial Intelligence.” The site revision number also changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check28 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1. The page continues to show a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page displays a 403 Forbidden error, replacing the study details with an access-denied message. This indicates a permissions problem rather than a change to the underlying study information.SummaryDifference22%

- Check49 days agoChange DetectedThe Study Documents section now includes revision v3.7.0, and revision v3.6.6 has been removed. This indicates a newer document version is available for review.SummaryDifference0.0%

- Check64 days agoChange DetectedRevision: v3.6.6 was added, replacing v3.6.5. This change reflects an incremental update to the page's versioning rather than alterations to study data or descriptions.SummaryDifference0.0%

- Check85 days agoChange DetectedThe website's revision tag was updated from v3.6.4 to v3.6.5. This represents a small platform update without altering study information on the page.SummaryDifference0.0%

Stay in the know with updates to KTE-C19 + Atezolizumab in DLBCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KTE-C19 + Atezolizumab in DLBCL Clinical Trial page.